Abstract. We identified patterns of differentially-expressed genes in cell lines derived from several pediatric solid tumors. Affymetrix Human Cancer G110 Arrays, carrying 1,700 cancer-associated genes, were applied to a panel of 11 cell lines originating from Ewing tumors (ETs), neuroblastomas, and malignant melanoma of soft parts. Hierarchical clustering clearly differentiated these 3 entities and revealed groups of 75, 102, and 36 gene probe-sets exhibiting tumor-type specific up-regulation in these cell lines, respectively. Whereas ET lines demonstrated increased expression of microtubuleassociated protein tau ( MAPT), protein phosphatase 1 regulatory subunit 1A (PPP1R1A), NIMA (never in mitosis gene a)-related kinase 2 (NEK2), and cyclin D1 (CCND1), neuroblastoma samples exhibited high expression of wingless-type mouse mammary tumor virus integration site family member 11 (WNT11), Drosophila frizzled homolog 2 (FZD2), and adenomatous polyposis coli (APC) which are involved in regulating free ß-catenin levels. These genes likely maintain tumor-specific characteristics and participate in key downstream regulatory mechanisms. We also correlated the expression levels of up-regulated genes in ETs with their chromosomal localization and compared these data to the comparative genomic hybridization profiles of the cell lines. We demonstrate that gains of genetic material contribute essentially to differential gene expression.
Introduction
Tumor progression occurs via the accumulation of genetic changes that permit independence from normal cellular and environmental requirements. These aberrations affect cellcycle regulation, apoptosis, signal transduction, cell adhesion, cytoskeletal structure, angiogenesis, and genomic stability itself. However, the processes of identifying the affected genes and of determining their roles in tumorigenesis, progression, and response to therapy have been challenging. One important approach to detect cancer-related genes is the identification of differentially-expressed transcripts either between tumors and their respective normal tissues or among various tumor entities. The development of DNA microarray technology (reviewed in refs. [1] [2] [3] [4] has provided the opportunity to simultaneously evaluate the expression patterns of thousands of genes by measuring their mRNA abundance. These techniques can be paired with data analysis tools (5) to facilitate very large-scale processing of gene expression data. The generation and comparison of these gene expression profiles allow the identification of multi-gene expression patterns which provide insight into regulatory mechanisms, cellular functions, and biochemical pathways (reviewed in refs. 4, 6) . To date, the variety of cell lines and tumor types studied employing microarray technology have illustrated its large potential to identify differentially-expressed genes on a genome-wide scale (7) .
We have, therefore, applied oligonucleotide microarrays to analyze cell lines derived from Ewing tumor (ET), neuroblastoma (NB), and malignant melanoma of soft parts (MMSP) ( Table I) . Together with rhabdomyosarcoma, lymphoma, and several other rare solid tumors affecting children and young adults, these tumors represent the group of small, round blue cell tumors of childhood; however, the distinction of these entities from each other still can present a diagnostic challenge to pathologists. In addition, the possible clinical outcomes for these tumors comprise a broad spectrum ranging from a complete cure to a rapid progression of disease even during multi-modal therapy. Therefore an accurate grouping of tumor subtypes based on detailed molecular characterization may be helpful in both diagnostic classification as well as prediction of cancer prognosis.
Here, we report the classification of 11 pediatric solid tumor cell lines into their respective tumor types based on their gene expression patterns. Furthermore, we describe lesionspecific gene clusters revealed by hierarchical clustering analysis of expression-microarray data and discuss the significance of several differentially-expressed genes within the context of understanding their roles in tumorigenesis. Finally, we present data obtained by comparative genomic hybridization (CGH) and compare these findings with results obtained from the gene expression microarrays.
Materials and methods
Cell culture. The 11 cell lines we studied are listed in Table I . The ET samples comprised CADO-ES-1, RD-ES, RM-82, SK-N-MC, VH-64, and WE-68. Our experiments also included GG-62, derived from an MMSP. The clinical data and the cytogenetic features for these 7 cell lines have been reviewed (8) . Four NB cell lines were investigated including Kelly, NGP, SH-EP, and SH-SY5Y (9-11). All cell lines were maintained as previously described (12) .
Complementary RNA preparation and microarray hybridization. The preparation and processing of labeled and fragmented cRNA targets is detailed by Affymetrix (Santa Clara, CA). Briefly, total RNAs were prepared from cells using TRIzol reagent (Life Technologies, Germany). A T7-(dT) 24 primer containing a T7 RNA-polymerase promoter site (Eurogentec, Belgium) was used to synthesize double-stranded, T7-tailed cDNAs directly from 20 µg of each total RNA as previously described (13) (SuperScript Choice System for cDNA Synthesis, Life Technologies). Biotinylated cRNAs were in vitro transcribed from 0.5 µg of each cDNA (biotinylated-11-CTP and -16-UTP; BioArray HighYield RNA Transcript Labeling Kit, Enzo Diagnostics, Farmingdale, NY) and fragmented.
Cocktails including labeled and fragmented cRNAs (10 µg) and hybridization controls were hybridized, in duplicate experiments, to Affymetrix Human Cancer G110 Arrays for 16 h at 45˚C (GeneChip Hybridization Oven). The microarrays were washed as required (Affymetrix) and stained using 10 µg/ml streptavidin-phycoerythrin (Molecular Probes, OR). Microarray images were obtained with a GeneArray Scanner (Hewlett Packard, Palo Alto, CA).
Microarray data analysis. GeneChip Analysis Suite 3.3 (Affymetrix) translated the scanned images into expression analysis files. To permit the direct comparison of all samples, the average fluorescence intensity of the entire arrays were scaled. Cluster analysis using Cluster 2.11 and TreeView 1.50 (14) permitted visualization of these results. To define a background fluorescence intensity value, all average difference (AD) intensity below 20 were assigned values of 20. [The AD value represents a numerical value for the expression level of a certain gene within a given sample. AD values are determined by the analysis software which calculates the average differences in intensities of all the probe pairs ('Perfect Match probe' vs 'Mismatch probe') for a particular gene]. Genes were then selected for cluster analysis based upon two criteria (see also Discussion): 1) an AD ratio, between the maximum AD value and the minimum AD value, of at least 6.0 across the 11 samples, and 2) at least half of the probe pairs for that gene being called 'positive' (i.e., a positive fraction value greater than 0.5) in at least one sample.
Quantitative real-time PCR. Our microarray cDNA samples were also evaluated by quantitative PCR for glyceraldehyde-3-phosphate dehydrogenase (GAPD) and gastrin-releasing peptide (GRP) expression using the LightCycler system (Roche Diagnostics, Mannheim, Germany). Double-stranded cDNA (2 µl) was amplified in a 20-µl reaction containing 2 mM MgCl 2 , 0.5 µM of each primer, and LightCycler-DNA Master SYBR Green I mix. GAPD cDNA was amplified using primers GAPD-1 (5'-gag tcc act ggc gtc ttc a-3') and GAPD-2 (5'-ggg gtg cta agc agt tgg t-3'), and primers GRP-1 (5'-ctg aag cag cag ctg aga ga-3') and GRP-2 (5'-gct atc ctc tga atc cca cg-3') were employed for quantifying GRP. An initial denaturation at 95˚C for 2 min was followed by 35 cycles of denaturation at 94˚C for 1 sec, annealing at 60˚C for 10 sec, and extension at 72˚C for 10 sec.
Quantitative analysis was performed using the LightCycler Software. We employed a relative quantification method in which the gene-expression levels from the cell lines were compared to data from a geometric dilution series (1:1, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64) of the highest-expressing sample, VH-64 (15) . The specificity of the PCR products was determined with the LightCycler Software's melting-curve analysis feature.
Comparative genomic hybridization (CGH).
Details of CGH analysis, microscopy, and digital image analysis techniques Table I . Pediatric solid tumor cell lines. 
a ET, Ewing tumor; NB, neuroblastoma; MMSP, malignant melanoma of soft parts.
are described elsewhere (16) . Briefly, 500 ng of labeled sample DNA, 300 ng of labeled reference DNA and 30 µg of human Cot 1 DNA (Life Technologies) were used to hybridize each metaphase spread. Labeled sequences were detected simultaneously using avidin-FITC (1:200) (Roche Diagnostics) and anti-DIG-rhodamine (1:40) (Roche Diagnostics). Average green-red ratios were calculated for each chromosome in 5-10 metaphases, and chromosomal regions with CGH ratio profiles surpassing the 50% thresholds (upper threshold 1.25, lower threshold 0.75) were defined as loci with copy number gains or losses, respectively.
Results
Gene expression patterns and cluster analysis. We investigated differential gene expression in 11 cell lines using Affymetrix Human Cancer G110 Arrays carrying 1,992 human probe-sets. These oligonucleotides represent over 1,700 genes which have been selected from the literature to be associated with cancer (Affymetrix). The cell lines were initially grouped as 7 ETs and 4 NBs; however, GG-62 had to be re-classified as a MMSP due to its expression of the EWS-ATF1 fusion gene [ Table I ; (17)]. As described by Ross et al (18) , we employed Figure 1 . Hierarchical clustering of expression microarray data. Normalized expression data for the 11 cell lines was generated by GeneChip Analysis Suite 3.3. An average intensity difference (AD) of 20 was assigned to all values below 20. All 1992 gene probe-sets were subjected to two criteria prior to cluster analysis: 1) an AD ratio (max AD/min AD) of at least 6.0 across the 11 samples, and 2) at least one sample demonstrating a positive fraction greater than 0.5. Cluster 2.11 and TreeView 1.50 were used to analyze and visualize the remaining 463 filtered probe-sets. In this cluster diagram, columns represent cell lines whereas rows determine individual genes. Cluster analysis divided the 11 cell lines into two major groups, with GG-62 (purple) being grouped with the neuroblastoma cell lines (green) as opposed to the Ewing tumor samples (blue). Relative gene expression is indicated by color and ranges from highly increased (intense red) to highly decreased (intense green). Clusters of 36 (purple), 75 (blue), and 102 (green) genes with tumor-type specific expression patterns are indicated; the latter 2 groups are shown in detail in Fig. 2 . a hierarchical clustering algorithm (19, 20) and colorization matrix (14, 21) in order to facilitate the visualization and interpretation of expression data (databases which contain complete expression data are available upon request).
In restricting our focus to analyze only those genes exhibiting significant differential expression, gene probe-sets were selected for cluster analysis based upon two criteria (see also Materials and methods): 1) an average difference (AD) intensity value ratio (max AD/min AD) of at least 6.0 across the 11 samples, and 2) at least one sample demonstrating a positive fraction greater than 0.5. Clustering of the 463 sets which fulfilled these requirements is shown in Fig. 1 . The cell lines were readily grouped into two sub-clusters: all 6 ET lines were grouped together while the MMSP and NB cell lines were assigned to the other sub-group. The 4 EWS-FLI1-expressing ET cell lines (RD-ES, SK-N-MC, VH-64, and WE-68) were clustered closely together with an EWS-ERGexpressing cell line, RM-82. In contrast, CADO-ES-1 which also expresses EWS-ERG clustered further away from the other ETs. The NB cell lines Kelly, NGP, and SH-SY5Y were clustered tightly together; however, SH-EP was determined to be as equally distant from these samples as the MMSP cell line, GG-62. We observed the specific up-regulation of clusters of 31 and 60 gene probe-sets in CADO-ES-1 and SH-EP, respectively. Furthermore, several gene clusters representing tumor-specific expression patterns were detected; in particular, groups of 75, 102 and 36 probe-sets exhibited markedly increased expression in ET, NB, and MMSP cell lines, respectively. Fig. 2 displays the ET and NB clusters in detail and lists the genes in these groups.
We observed a cluster of 64 genes, depicted by 75 probesets, exhibiting increased expression in ET cell lines compared to NB lines and GG-62 ( Fig. 2A) . These include insulin-like growth factor 1 [IGF1; (22) ], cellular myelocytomatosis viral oncogene homolog [MYC; (23) ], and gastrin-releasing peptide [GRP; (24) ]. Furthermore, several genes previously unassociated with ET pathology are found in this cluster including microtubule-associated protein tau (MAPT), protein phosphatase 1 regulatory subunit 1A (PPP1R1A), NIMA (never in mitosis gene a)-related kinase 2 (NEK2), and protein kinase C ß1 (PRKCB1).
A cluster of 102 probe-sets, representing 93 genes, is characterized by increased expression in the NB cell lines (Fig. 2B) including NB-derived v-myc avian myelocytomatosis viral related oncogene [MYCN; (25) ] and insulin-like growth factor 2 [IGF2; (26) ]. An IGF1b probe-set, designed to detect a special splice variant of IGF1, is also found within this group while, as mentioned above, two other probe-sets for IGF1 are located within the ET cluster. Other genes include winglesstype mouse mammary tumor virus integration site family member 11 (WNT11), Drosophila frizzled homolog 2 (FZD2), and adenomatous polyposis coli (APC); in fact, these 3 genes are involved in a common signaling pathway (27) .
Validation of microarray experiments. Each sample hybridization was performed twice in order to check the reproducibility of our results. Scatter plots of the AD values from duplicate hybridizations were generated, and a representative graph is shown in Fig. 3A . The vast majority of the highly-variable data points in the low-signal range (colored red) represent 'absent'-called genes which are removed by our filter criteria prior to cluster analysis. In contrast, a second graph comparing two different cell lines reveals highly-variable expression data, and even 'present'-called genes (colored blue) at the higher-signal ranges exhibit dramatic variation (Fig. 3B) . As mentioned earlier, we focused our attention only to those genes with reliable and dramatic differential expression; hence, we applied our filter criteria to select only those 'present'-called genes exhibiting a 6-fold difference in expression across our 11 samples.
Furthermore, real-time PCR using the LightCycler system was used as an independent method for assessing relative gene expression. GRP-expression levels, for example, determined using quantitative PCR for 6 ET cell lines and 3 NB samples were highly comparable to expression-microarray data (Fig. 4) . We obtained the same order of these 9 samples when they were ranked according to relative GRP-expression.
Gene expression patterns and comparative genomic hybridization (CGH).
To determine factors which may be responsible for variations of gene expression within a single defined tumor entity we analyzed a subset of genes which showed noticeable differences in their expression levels among the 6 ET lines only. We grouped these genes according to their chromosomal localization and compared the data to the CGH profiles of the tumor cell lines. To select for the most authentic expression data, the positive fraction criterion was raised to 0.65 and only probe-sets showing a minimum AD value of 100 (i.e., at least five times the defined background level) were included. One hundred and thirty probe-sets corresponding to 120 different genes fulfilled the criterion of an AD-ratio of at least 2.0 within the group of ETs comparing the most abundant expressing cell line to the median and whose localization on the chromosome were available from the LocusLink (www.ncbi.nih.gov/LocusLinc) or the GeneCards (http://bioinfo.weizmann.ac.il/cards) databases.
On average, we found 5.8 gains and 4.7 losses of chromosomal material in the 6 ET cell lines. The most obvious chromosome gains revealed by CGH could be correlated to increases in gene expression detected by oligonucleotide microarrays, and these results are summarized in Table II . For example, RD-ES exhibits increased expression of chromosome 1q genes including cellular retinoic acid-binding protein 2 (CRABP2), laminin Á 1 (LAMC1), and phosphatidylinositol-glycan-class C (PIGC), while WE-68 additionally expresses high levels of discoidin domain receptor family member 2 (DDR2) and interferon-Á induced protein (IFI16) genes. Correspondingly, both RD-ES and WE-68 harbor gains of material from 1q (Fig. 5) . Similarly, gains of chromosome 3q, 11q, 15q, and 17q were correlated with increased expression of genes from those regions in SK-N-MC, RD-ES, WE-68, and CADO-ES-1, respectively, and these genes are also listed in Table II. However, there are also several examples where increases in expression of genes localized in the same chromosomal region are not reflected by gains of genetic material. For instance, using microarrays, an up-regulation of genes was detected on chromosomes 2q, 5q, 19p, 19q, and 22q in CADO-ES-1; on 3p, 10q, and 14q in WE-68; and on 2p in VH-64. Nevertheless, none of these regions were demonstrated by CGH to be present in abnormal copy-numbers (data not shown).
Discussion
To discover characteristic functional pathways which are involved in the formation and progression of solid tumors of childhood, we analyzed cell lines derived from ET, NB, and MMSP by employing DNA microarray technology. We generated expression profiles of these cell lines based on the mRNA abundance of about 1,700 genes which have been selected from the literature to be associated with cancer (Affymetrix). To identify genes which are reliably and noticeably differentially expressed among the cell lines, we applied two filter criteria to select genes for contribution to the expression profiles. The influences of possible falsepositive signals from the arrays was minimized first by including only those genes for which at least half of their probe-cell pairs were called 'positive' (hence, a positive fraction greater than 0.5) in at least one of the 11 samples. The second criterion, the variation of gene expression among the cell lines, is given by the ratio of the maximum and the minimum 'average difference' (AD) expression-intensity values, for each gene, across the 11 samples. We included only genes with such AD ratios greater than or equal to 6.0. A total of 463 gene probe-sets (23.2%) passed both these filter criteria. Furthermore, the reproducibility of our data was demonstrated by comparing the AD values from duplicate hybridizations using scatter graphs. Quantitative PCR was used to validate expression-microarray data in the case of GRP.
Applying cluster analysis with these 463 differentiallyexpressed genes, the 11 tumor cell lines could clearly be distinguished into their respective tumor types. In addition, gene clusters, consisting of similarly-regulated genes in ETs or NBs, were observed to harbor known tumor-characteristic genes as well as those which have not yet been reported to play a crucial role in either of these tumor types. Among others, the well-characterized ET-associated genes we observed include MYC (23) , GRP (24) , and IGF1 (28) . We also identified glutathione-S-transferase M5 (GSTM5) to be present in the ET cluster. Furthermore, v-yes-1 Yamaguchi sarcoma viral related oncogene homolog (LYN) (29) , IGF2 (30) , and MYCN (25) (when amplified at the genomic level) were determined to be characteristically up-regulated in NBs. Similarly, a NB-associated increased expression of GATAbinding protein 2 (GATA2) was seen. Our findings of upregulated GSTM5 and GATA2 expression in ETs and NBs, respectively, are in agreement with those from a recent study by Khan et al (31) which also presents expression-profiling results of small blue round cell tumors. Using cDNA arrays and artificial neural networks, they were able to categorize ETs, NBs, rhabdomyosarcomas, and Burkitt lymphomas according to their respective tumor types based upon analyses of gene-expression signatures.
For our analysis, we were especially interested in groups of genes, rather than in single up-or down-regulated genes, which belong to the same functional pathway. For example, the ET-cluster genes include MAPT, PPP1R1A, and NEK2 which are all related to centrosome functioning. NEK2 encodes a cell-cycle regulated kinase which associates with centrosomes and directly affects their structures. NEK2 substrates include centrosomal NEK2-associated protein 1 (C-NAP1) and protein phophatase 1 (PP1), and a ternary complex of these three proteins has recently been demonstrated (32) . Although PP1 actually reduces NEK2 activity, phosphatase inhibitors such as PPP1R1A alleviate this repression. Therefore, the observed up-regulation of both PPP1R1A and NEK2 in ET cells may have profound implications on the potential for NEK2 to affect centrosome structure and, therefore, cell-cycle regulation. In fact, several key cell-cycle associated genes are also grouped into the ET cluster including cyclin D1 (CCND1) and cyclin-dependent kinase inhibitor 2A (CDKN2A). More- 
Ewing tumor cell line(s) exhibiting the highest relative gene expression.
over, our observation of increased MAPT-expression is significant given the involvement of tau proteins in nucleating microtubule assembly over centrosomes (33) . These results support the idea proposed by Arvand et al (34) that EWS-FLI1, and possibly EWS-ERG, proteins contribute to the deregulation of cell-cycle genes including ubiquitin carrier protein E2-C (UBCH10). In fact, we observed an average 1.5-fold increase in UBCH10 expression in our ET samples vs NB lines. In ETs, several of these differentially-expressed genes may be constitutively-activated targets of chimeric EWS-FLI1 or EWS-ERG transcription factors which result from t(11;22) and t(21;22) rearrangements, respectively (35) . We hypothesize that these up-regulated genes are equally responsible for maintaining transformed or malignant phenotypes in this entity, and, therefore, can serve as potential targets for novel therapies.
Genes with increased expression in the NB cell lines (found within the NB cluster) include WNT11, FZD2, and APC which are all involved in regulating levels of free ß-catenin, a potent transcriptional activator that modulates cell proliferation (reviewed in ref. 27 ). High protein levels of APC, which is actually responsible for inhibiting ß-catenin by targeting it for proteasome degradation, has been observed in NB cell lines (36) . On the other hand, WNT and its receptor, FZD, both act against APC to prevent ß-catenin degradation. The opposing actions of these and possibly other genes may serve in fine-tuning the levels of free ß-catenin. In fact, a crucial role for the WNT-signaling pathway has been implicated in colorectal cancer (reviewed in ref. 37 ). Lickert et al (38) demonstrated that Wnt/ß-catenin-signaling normally induces caudal type homeo-box transcription factor 1 (Cdx1) expression in the developing mouse embryonic intestine; moreover, a down-regulation of human CDX1 and/or CDX2 expression has been associated with colorectal tumorigenesis (39) . In our experiments, neither CDX1 nor CDX2 expression could be detected in any of the NB cells even though other homeobox protein genes, HOXD8 and HOXD10, were found in the NB cluster. Other genes for proteins which modulate ß-catenin activity were either highly expressed [Drosophila disheveled homolog 1 (DVL1), protein phosphatase 2 regulatory subunit B56 ·-isoform (PPP2R5A), and casein kinase 1 Á 2 (CSNK1G2)] or absent [p300/CBP-associated factor (PCAF)] across all the cell lines; therefore, these probe-sets were not considered to be 'differentially expressed' and were not included in the cluster analysis. However, we did observe an average 1.9-fold increase in expression of DVL1, a positive regulator of ß-catenin, in NB vs ET lines. Our results suggest the involvement of WNT-signaling and ß-catenin activity in deregulating cell division in NBs. A further investigation of other important WNT-signaling genes including axin 2 (AXIN2), lymphoid enhancer-binding factor 1 (LEF1), and CTNNB1 (which encodes ß-catenin) is warranted.
While our results in general support the findings of others, we were not able to draw clear conclusions on expression for several genes including IGF1 and basic fibroblast growth factor (bFGF). The role of IGF1 in mediating the proliferation and survival of NB cells has been characterized. Moreover, studies have demonstrated a close relationship between IGF1 and increased MYCN expression (40, 41) . However, redundant IGF1 probe-set pairs were grouped far apart during cluster analysis; consequently, we observed the grouping IGF1b to the NB cluster while two other IGF1 probe-sets were placed within the ET cluster. We also observed the increased expression of bFGF in our NB cell lines even though the bFGF pathway is thought by some to be important for the malignant phenotype of ET (42) . However, others have demonstrated that bFGF actually decreases ET growth via apoptosis (43) .
Although cluster analysis was able to differentiate between NB and ET cell lines, we made several unexpected observations within the NB and ET sub-groups themselves. For the NB cell lines, the clustering of SH-EP apart from SH-SY5Y, Kelly, and NGP is not surprising given the fact that SH-EP has been characterized as an atypical NB exhibiting epithelial differentiation (44) . However, the association of SH-SY5Y with Kelly and NGP is somewhat unexpected given a 100-fold MYCN amplification and high MYCN-expression in the latter two cell lines while this gene is neither amplified nor highly expressed in SH-SY5Y. Amplification of the MYCN proto-oncogene occurs in 20-25% of NB cases and is a reliable marker of aggressive clinical behavior (45) . Moreover, a recent study of MYCN-expression in non-MYCN-amplified NBs stresses the prognostic importance of MYCN amplification (46) ; even so, we did not detect high MYCN-expression in our NB cells without MYCN amplification. The association between MYCN amplification and CD44 suppression has been well studied (47) (48) (49) ; however, in the two NB cell lines without MYCN amplification, we only detected strong CD44 expression in SH-EP. Nevertheless, it is critical to evaluate CD44 expression by array technology because CD44 splicevariations and post-translational modifications, such as hyaluronization, may alter protein function.
Currently one of the main reasons for looking at differential gene-expression in cancer is to obtain clues for a molecular definition of clinical prognostic subgroups to optimize treatment protocols. With current treatment strategies, the overall successful outcome of ET patients is 50-60%. Patients presenting without clinically detectable metastasis at the time of diagnosis and who also show good response to chemotherapy (defined by histological or imaging techniques) were positively correlated with a good outcome (50) . From a molecular genetic point of view, it was noted that patients with localized disease show a significantly more favorable prognosis if the tumor expresses the EWS exon 7/FLI1 exon 6 fusion transcript (51, 52) . Assuming that the complete biological behavior, including tendency to form metastases or sensitivity to certain chemotherapeutic drugs, is reflected by the expression profile of the tumor cells, we attempted to determine genetic factors which may be responsible for variations of gene expression within this tumor entity.
Of the 6 ET cell lines, CADO-ES-1 and RM-82 harbor EWS-ERG fusions while the remaining 4 samples express the more common EWS-FLI1 transcript. CADO-ES-1 exhibited a dramatically different expression pattern not only when compared to the other ETs but also in contrast to RM-82. This resulted in CADO-ES-1 clustering further apart from the remaining ETs than expected. In fact, CADO-ES-1 is derived from an ET in a Japanese individual whereas the other 5 ETs were obtained from Caucasian patients (8) . Among the 4 EWS-FLI1-expressing lines, cluster analysis could not separate those expressing the type I fusion (EWS exon 7/FLI1 exon 6) from those with type II fusions (EWS exon 7/FLI1 exon 5) (51). In fact, SK-N-MC and WE-68 harbor type I fusions whereas RD-ES and VH-64 express type II transcripts. However, cluster analysis determined SK-N-MC and VH-64 to have the most similar expression patterns, and both of these cell lines were equally different from RD-ES or WE-68. Apparently, factors other than fusion-transcript type have a more lasting effect on the expression pattern of the cell lines. To find clues for the mechanism of differential regulation within this tumor entity, we analyzed genes which showed noticeable differences in their expression levels among the 6 ET lines. Then, we compared these microarray data with the corresponding CGH profiles in an attempt to relate gains of genomic material with increases in gene expression. Although a stringent statistical analysis was not performed, because CGH is not a quantitative method and chromosome copy-numbers are not reported by numerical values, our examination demonstrated for some chromosomes a strong correlation between regions where genetic material is gained and the co-upregulation of co-localized genes. These findings, which suggest that genomic gains detected by CGH may contribute directly toward increased gene expression, have also been observed in rhabdomyosarcomas and breast cancer (53, 54) . Our ET cell lines harbor, in general, higher average numbers of genomic gains and losses (5.8 and 4.7, respectively) compared to primary tumors [1.6 gains and 0.4 losses; (55)]. One should keep in mind, therefore, that the analysis of additional genomic gains harbored by cell lines may not necessarily contribute directly towards the understanding of tumorigenesis even if the gains do result in increased gene expression. However, gene expression analysis and correlation with clinical data is mandatory to further determine which genes are crucial for tumor progression in these different entities.
The ability permitted by oligonucleotide microarrays to study the expression patterns of thousands of genes simultaneously has provided unprecedented opportunities for detecting and identifying cancer-related genes in a rapid and reliable fashion. This tool has been applied to study a variety of cell lines as well as primary samples (7) . However, array methods are still in their infancy and, therefore, have not yet been extensively applied to comparing gene expression profiles of either different cell lines or primary tumors derived from several tumor entities. Our results provide a more detailed picture of how certain genes are intricately involved in the progression of ET, NB, and MMSP. Nevertheless, expression of microarray data requires careful analysis and interpretation, and functional experiments are required to evaluate the in silico results we have obtained thus far. These studies provide a deeper understanding of these individual genes in complex cellular networks and of their contribution to the etiology of cancer.
